个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共11条记录   New Antidepressant Drugs: Beyond Monoaminergic Mechanisms [作者：Alamo, C; Lopez-Munoz, F,期刊：Current Pharmaceutical Design, 页码：1559-1562 , 文章类型： Editorial Material，,卷期：2009年15-14] Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today [作者：Lopez-Munoz, F; Alamo, C,期刊：Current Pharmaceutical Design, 页码：1563-1586 , 文章类型： Review，,卷期：2009年15-14] The 1950s saw the clinical introduction of the first two specifically antidepressant drugs: iproniazid, a monoamine-oxidase inhibitor that had been used in the treatment of tuberculosis, and imipramine, the first drug in... CRF Receptors as a Potential Target in the Development of Novel Pharmacotherapies for Depression [作者：Valdez, GR,期刊：Current Pharmaceutical Design, 页码：1587-1594 , 文章类型： Review，,卷期：2009年15-14] Depression is a highly prevalent form of mental illness. This condition is often considered a stress-related disorder because some form of stressful life event frequently triggers depressive symptoms. Corticotropin-relea... Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders [作者：Machado-Vieira, R; Salvadore, G; Ibrahim, LA; Diaz-Granados, N; Zarate, CA,期刊：Current Pharmaceutical Design, 页码：1595-1611 , 文章类型： Review，,卷期：2009年15-14] There have been no recent advances in drug development for mood disorders in terms of identifying drug targets that are mechanistically distinct from existing ones. As a result, existing antidepressants are based on deca... Opiates as Antidepressants [作者：Berrocoso, E; Sanchez-Blazquez, P; Garzon, J; Mico, JA,期刊：Current Pharmaceutical Design, 页码：1612-1622 , 文章类型： Review，,卷期：2009年15-14] The pathophysiology of mood disorders involves several genetic and social predisposing factors, as well as a dysregulated response to a chronic stressor, i.e. chronic pain. Our present view that depression involves a dys... Endocannabinoids in the Treatment of Mood Disorders: Evidence from Animal Models [作者：Bambico, FR; Duranti, A; Tontini, A; Tarzia, G; Gobbi, G,期刊：Current Pharmaceutical Design, 页码：1623-1646 , 文章类型： Review，,卷期：2009年15-14] Among all mental disorders, major depression has the highest rate of prevalence and incidence of morbidity. Currently available antidepressant therapies have limited efficacies; consequently, research on new drugs for th... Tachykinin Receptors as Therapeutic Targets in Stress-Related Disorders [作者：Ebner, K; Sartori, SB; Singewald, N,期刊：Current Pharmaceutical Design, 页码：1647-1674 , 文章类型： Review，,卷期：2009年15-14] The first report demonstrating the therapeutic efficacy of an orally applied neurokinin-1 (NK1) receptor antagonist in depression was published 10 years ago. Although there were difficulties to reproduce this particular ... Melatonin Receptor Agonist Agomelatine: A New Drug for Treating Unipolar Depression [作者：Bourin, M; Prica, C,期刊：Current Pharmaceutical Design, 页码：1675-1682 , 文章类型： Review，,卷期：2009年15-14] Agomelatine markedly differs from other classes of antidepressant drugs: its primary molecular targets in vivo are the melatonin MT1 and MT2 receptors, where it acts as a potent agonist, and the 5-HT2C receptors, where i... New Approaches to Antidepressant Drug Design: Cytokine-Regulated Pathways [作者：Nishida, A; Miyaoka, T; Inagaki, T; Horiguchi, J,期刊：Current Pharmaceutical Design, 页码：1683-1687 , 文章类型： Review，,卷期：2009年15-14] Monoamine oxidase inhibitor and tricyclic antidepressants have been serendipitously used for the treatment of depression for more than half a century and subsequently found to promote monoaminergic signals in the brain. ... Cyclic AMP-Specific Phosphodiesterase-4 as a Target for the Development of Antidepressant Drugs [作者：Zhang, HT,期刊：Current Pharmaceutical Design, 页码：1688-1698 , 文章类型： Review，,卷期：2009年15-14] Phosphodiesterase-4 (PDE4), one of eleven PDE enzyme families, specifically catalyzes hydrolysis of cyclic AMP (cAMP); it has four subtypes (PDE4A-D) with at least 25 splice variants. PDE4 plays a critical role in the co... Antidepressants, beta-Arrestins and GRKs: From Regulation of Signal Desensitization to Intracellular Multifunctional Adaptor Functions [作者：Golan, M; Schreiber, G; Avissar, S,期刊：Current Pharmaceutical Design, 页码：1699-1708 , 文章类型： Review，,卷期：2009年15-14] G protein-coupled receptors (GPCR) have generated considerable interest in the pharmaceutical industry as drug targets. Theories concerning antidepressant targets of action suggested pre-synaptic monoamine reuptake mecha...